compounding semaglutide fda news Warns Against Using Compounded The End of Compounded Semaglutide:

Higher ARB use in the GLP-1RA group may contribute modest positive confounding given evidence for ARB-mediated aortic protection

The FDA has also warned patients and providers about dosing errors associated with compounded injectable semaglutide products, including errors involving measurement units and self-administration that have required hospitalization

We offer GLP-1/GIP weight loss treatments to help patients reach their fitness goals

doi: 10.2337/db22-146-OR

Referenced for the GLP-1 / triple-agonist market-size projection

The most common ones are stomach-related and tend to be worst right after a dose increase